Objective: The objective was to determine the impact of carbamazepine on the pharmacokinetics and pharmacodynamics of the etonogestrel contraceptive implant.
Study Design: We enrolled healthy, reproductive-age women using an etonogestrel implant for 1-3 years. We measured etonogestrel levels at baseline and following 3 weeks of coadministered carbamazepine titrated up to 300 mg twice daily. We also evaluated for ovarian follicle-like structures and endometrial thickness using transvaginal ultrasound at the baseline and 3-week visits.
Results: We enrolled 13 women; 10 completed study procedures. Participants' mean age was 25.6 years (±5.6), mean body mass index was 30.4 (±7.3), and median duration of implant use was 23 months (range 15-35). The median etonogestrel concentrations before and after carbamazepine coadministration were 158.1 pg/mL (range 128-347) and 50.9 pg/mL (range 39-202), respectively (p=.005). In 8 of 10 subjects, the etonogestrel concentration was below the threshold for ovulatory suppression (<90 pg/mL) after carbamazepine coadministration. The number of ovarian follicle-like structures and endometrial thickness did not significantly change before and after carbamazepine coadministration.
Conclusions: Women using a contraceptive implant experienced significant reductions in etonogestrel concentrations following coadministration of 600 mg of carbamazepine. We did not find significant pharmacodynamic changes during this abbreviated follow-up period.
Implications: Carbamazepine use significantly reduces serum etonogestrel concentrations in women using an etonogestrel contraceptive implant, with the majority of participants having etonogestrel concentrations below the threshold for ovulatory suppression. Our findings suggest that treatment with carbamazepine might increase the risk of pregnancy in etonogestrel implant users.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2017.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention.
J Control Release
January 2025
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Northern Ireland BT9 7BL, United Kingdom. Electronic address:
Article Synopsis
- New multipurpose prevention technologies for women prioritize reducing HIV risks and preventing unwanted pregnancies, promoting greater sexual health choices.
- A novel long-acting injectable platform combines the HIV drug MIV-150 and the contraceptive etonogestrel using a specially designed D-peptide that forms a drug-releasing hydrogel after injection.
- The technology shows promising biostability, low toxicity, and sustained delivery of both drugs in animal models for nearly 50 days, indicating its potential for effective long-term use.
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women with HIV.
J Infect Dis
October 2024
Department of Pediatrics, University of California, Los Angeles, Los Angeles, California, USA.
Background: HIV-1 antiretroviral therapy (ART) alters hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen specific manner. We explored the role of the IVR on vaginal microbial communities, vaginal short chain fatty acids (SCFAs), vaginal HIV shedding, and the effect of vaginal microbes on hormone concentrations in cisgender women with HIV (WWH).
Methods: Vaginal microbes were assessed by 16S RNA sequencing of weekly vaginal swabs, vaginal SCFA by mass spectrometry, HIV-1 shedding by nucleic acid amplification on vaginal aspirates, and bacterial vaginosis by Nugent scoring from 74 participants receiving an etonorgestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (N=25), efavirenz-based ART (N=25), or atazanavir-based ART (N=24).
Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratories.
Contraception
February 2025
Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address:
Article Synopsis
- This study aimed to compare how different laboratories measure etonogestrel, a contraceptive hormone, focusing on accuracy and precision across six labs (five academic and one commercial).
- In tests with prepared serum and plasma samples, four labs achieved accurate results within ±15% of expected concentrations, while high precision was demonstrated, with minimal variation across results.
- However, while individual labs generally correlated well with a reference lab for serum samples, some showed biases resulting in consistently higher or lower readings, highlighting variability in etonogestrel measurement methods across different facilities.
Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
PLoS One
July 2024
Department of Epidemiology, George Washington University, Washington, DC, United States of America.
Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
View Article and Find Full Text PDFThe influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users.
Contraception
December 2024
University Hospitals Cleveland Medical Center and Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland, OH, USA.
Objective: To evaluate how diet, exercise, and substance use influence serum etonogestrel concentrations among contraceptive implant users.
Study Design: We conducted a cross-sectional analysis of healthy, reproductive-age etonogestrel implant users. We assessed participants' current diet, exercise, and substance (alcohol, tobacco, marijuana) use habits while simultaneously measuring serum etonogestrel concentrations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!